---
title: "Bank of America Securities Remains a Buy on Travere Therapeutics (TVTX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286542034.md"
description: "Bank of America Securities analyst Jason Zemansky has maintained a Buy rating on Travere Therapeutics (TVTX) with a price target of $50.00. The stock closed at $44.10. The analyst consensus is a Strong Buy with an average price target of $53.42, indicating a 21.13% upside. H.C. Wainwright also reiterated a Buy rating with a $57.00 target."
datetime: "2026-05-15T09:49:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286542034.md)
  - [en](https://longbridge.com/en/news/286542034.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286542034.md)
---

# Bank of America Securities Remains a Buy on Travere Therapeutics (TVTX)

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Travere Therapeutics yesterday and set a price target of $50.00. The company’s shares closed yesterday at $44.10.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Zemansky is a 5-star analyst with an average return of 19.9% and a 56.33% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Biogen, Insmed, and Ligand Pharma.

Currently, the analyst consensus on Travere Therapeutics is a Strong Buy with an average price target of $53.42, representing a 21.13% upside. In a report released on May 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $57.00 price target.

### Related Stocks

- [TVTX.US](https://longbridge.com/en/quote/TVTX.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)
- [LGND.US](https://longbridge.com/en/quote/LGND.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Travere’s US$525 Million Convertible Refi Might Change The Case For Investing In Travere Therapeutics (TVTX)](https://longbridge.com/en/news/286451880.md)
- [Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News](https://longbridge.com/en/news/286157454.md)
- [Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)](https://longbridge.com/en/news/286542293.md)
- [LifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/286679543.md)
- [Barclays Remains a Buy on Oruka Therapeutics (ORKA)](https://longbridge.com/en/news/286389801.md)